ERBB2 and hematologic disorder: Currently, over one hundred ADCs are under clinical investigation, and more than a dozen ADCs have received approval for the treatment of hematological malignancies and solid tumors; in particular, T-DM1, a HER2-targeting ADC, was the first approved ADC in solid tumors for HER2-positive metastatic breast cancer [213–215].